Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Identifieur interne : 001094 ( Main/Exploration ); précédent : 001093; suivant : 001095Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Auteurs : Jean-François RossignolSource :
- Journal of Infection and Public Health [ 1876-0341 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Essais cliniques comme sujet, Humains, Infections à coronavirus (traitement médicamenteux), Modèles animaux de maladie humaine, Réplication virale (), Thiazoles (pharmacologie), Thiazoles (usage thérapeutique).
- MESH :
- pharmacologie : Antiviraux, Thiazoles.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Antiviraux, Thiazoles.
- Animaux, Coronavirus du syndrome respiratoire du Moyen-Orient, Essais cliniques comme sujet, Humains, Modèles animaux de maladie humaine, Réplication virale.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Clinical Trials as Topic, Coronavirus Infections (drug therapy), Disease Models, Animal, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (physiology), Thiazoles (pharmacology), Thiazoles (therapeutic use), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Thiazoles.
- chemical , therapeutic use : Antiviral Agents, Thiazoles.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Replication.
- drug therapy : Coronavirus Infections.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans.
Abstract
Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits
Url:
DOI: 10.1016/j.jiph.2016.04.001
PubMed: 27095301
PubMed Central: 7102735
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000E38
- to stream Pmc, to step Curation: 000E38
- to stream Pmc, to step Checkpoint: 000A56
- to stream PubMed, to step Corpus: 001157
- to stream PubMed, to step Curation: 001157
- to stream PubMed, to step Checkpoint: 002A36
- to stream Ncbi, to step Merge: 001584
- to stream Ncbi, to step Curation: 001584
- to stream Ncbi, to step Checkpoint: 001584
- to stream Main, to step Merge: 001098
- to stream Main, to step Curation: 001094
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27095301</idno>
<idno type="pmc">7102735</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102735</idno>
<idno type="RBID">PMC:7102735</idno>
<idno type="doi">10.1016/j.jiph.2016.04.001</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E38</idno>
<idno type="wicri:Area/Pmc/Curation">000E38</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E38</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A56</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A56</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:27095301</idno>
<idno type="wicri:Area/PubMed/Corpus">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001157</idno>
<idno type="wicri:Area/PubMed/Curation">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001157</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A36</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A36</idno>
<idno type="wicri:Area/Ncbi/Merge">001584</idno>
<idno type="wicri:Area/Ncbi/Curation">001584</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001584</idno>
<idno type="wicri:doubleKey">1876-0341:2016:Rossignol J:nitazoxanide:a:new</idno>
<idno type="wicri:Area/Main/Merge">001098</idno>
<idno type="wicri:Area/Main/Curation">001094</idno>
<idno type="wicri:Area/Main/Exploration">001094</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</title>
<author><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</author>
</analytic>
<series><title level="j">Journal of Infection and Public Health</title>
<idno type="ISSN">1876-0341</idno>
<idno type="eISSN">1876-035X</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (physiology)</term>
<term>Thiazoles (pharmacology)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Réplication virale ()</term>
<term>Thiazoles (pharmacologie)</term>
<term>Thiazoles (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials as Topic</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Modèles animaux de maladie humaine</term>
<term>Réplication virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Summary</title>
<p>Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits <italic>in vitro</italic>
activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include <italic>in vitro</italic>
mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name>
</author>
<author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name>
</author>
<author><name sortKey="Arabi, Y" uniqKey="Arabi Y">Y. Arabi</name>
</author>
<author><name sortKey="Alotaibi, B" uniqKey="Alotaibi B">B. Alotaibi</name>
</author>
<author><name sortKey="Rao, M" uniqKey="Rao M">M. Rao</name>
</author>
<author><name sortKey="Mccloskey, B" uniqKey="Mccloskey B">B. McCloskey</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Chiappa, L" uniqKey="Chiappa L">L. Chiappa</name>
</author>
<author><name sortKey="Ciucci, A" uniqKey="Ciucci A">A. Ciucci</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Belardo, G" uniqKey="Belardo G">G. Belardo</name>
</author>
<author><name sortKey="Cenciarelli, O" uniqKey="Cenciarelli O">O. Cenciarelli</name>
</author>
<author><name sortKey="La Frazia, S" uniqKey="La Frazia S">S. La Frazia</name>
</author>
<author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J.F. Rossignol</name>
</author>
<author><name sortKey="Santoro, M G" uniqKey="Santoro M">M.G. Santoro</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Lam, K K Y" uniqKey="Lam K">K.K.Y. Lam</name>
</author>
<author><name sortKey="Zheng, X" uniqKey="Zheng X">X. Zheng</name>
</author>
<author><name sortKey="Forestieri, R" uniqKey="Forestieri R">R. Forestieri</name>
</author>
<author><name sortKey="Balgi, A D" uniqKey="Balgi A">A.D. Balgi</name>
</author>
<author><name sortKey="Nodwell, M" uniqKey="Nodwell M">M. Nodwell</name>
</author>
<author><name sortKey="Volett, S" uniqKey="Volett S">S. Volett</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Romark Laboratories" uniqKey="Romark Laboratories">Romark Laboratories</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Cao, J" uniqKey="Cao J">J. Cao</name>
</author>
<author><name sortKey="Forrest, J C" uniqKey="Forrest J">J.C. Forrest</name>
</author>
<author><name sortKey="Zhang, X" uniqKey="Zhang X">X. Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Hong, S K" uniqKey="Hong S">S.K. Hong</name>
</author>
<author><name sortKey="Kim, H G" uniqKey="Kim H">H.G. Kim</name>
</author>
<author><name sortKey="Chong, C S" uniqKey="Chong C">C.S. Chong</name>
</author>
<author><name sortKey="Choi, I S" uniqKey="Choi I">I.S. Choi</name>
</author>
<author><name sortKey="Lee, J B" uniqKey="Lee J">J.B. Lee</name>
</author>
<author><name sortKey="Park, S Y" uniqKey="Park S">S.Y. Park</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Haffizulla, J" uniqKey="Haffizulla J">J. Haffizulla</name>
</author>
<author><name sortKey="Hartman, A" uniqKey="Hartman A">A. Hartman</name>
</author>
<author><name sortKey="Hoppers, M" uniqKey="Hoppers M">M. Hoppers</name>
</author>
<author><name sortKey="Resnick, H" uniqKey="Resnick H">H. Resnick</name>
</author>
<author><name sortKey="Samudrala, S" uniqKey="Samudrala S">S. Samudrala</name>
</author>
<author><name sortKey="Ginocchio, C" uniqKey="Ginocchio C">C. Ginocchio</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Rossignol, Jean Francois" sort="Rossignol, Jean Francois" uniqKey="Rossignol J" first="Jean-François" last="Rossignol">Jean-François Rossignol</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001094 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001094 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:7102735 |texte= Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27095301" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |